Central Bank & Trust’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.77M Buy
11,017
+8,905
+422% +$1.92M 0.39% 63
2026
Q1
$459K Buy
2,112
+150
+8% +$33.3K 0.07% 142
2025
Q4
$448K Sell
1,962
-274
-12% -$62.4K 0.07% 137
2025
Q3
$518K Buy
2,236
+149
+7% +$30.3K 0.08% 134
2025
Q2
$387K Sell
2,087
-29
-1% -$5.39K 0.06% 146
2025
Q1
$443K Buy
2,116
+5
+0.2% +$972 0.07% 141
2024
Q4
$375K Sell
2,111
-1,235
-37% -$227K 0.06% 149
2024
Q3
$661K Hold
3,346
0.09% 134
2024
Q2
$574K Hold
3,346
0.08% 128
2024
Q1
$609K Sell
3,346
-68
-2% -$11.7K 0.09% 128
2023
Q4
$529K Buy
3,414
+1,692
+98% +$247K 0.08% 136
2023
Q3
$257K Hold
1,722
0.04% 153
2023
Q2
$232K Buy
1,722
+108
+7% +$15.8K 0.04% 160
2023
Q1
$257K Sell
1,614
-422
-21% -$64.5K 0.05% 156
2022
Q4
$329K Sell
2,036
-101
-5% -$15.5K 0.06% 149
2022
Q3
$287K Buy
2,137
+287
+16% +$41.2K 0.06% 150
2022
Q2
$283K Buy
1,850
+106
+6% +$16.2K 0.06% 161
2022
Q1
$283K Buy
1,744
+211
+14% +$30.6K 0.05% 157
2021
Q4
$208K Buy
1,533
+500
+48% +$59.1K 0.03% 167
2021
Q3
$111K Hold
1,033
0.02% 186
2021
Q2
$116K Hold
1,033
0.02% 187
2021
Q1
$112K Hold
1,033
0.02% 180
2020
Q4
$111K Buy
1,033
+100
+11% +$9.61K 0.02% 171
2020
Q3
$82K Buy
933
+200
+27% +$18.8K 0.02% 177
2020
Q2
$72K Hold
733
0.01% 170
2020
Q1
$56K Sell
733
-500
-41% -$42.6K 0.01% 171
2019
Q4
$109K Sell
1,233
-23
-2% -$1.91K 0.02% 160
2019
Q3
$95K Sell
1,256
-433
-26% -$29.7K 0.02% 164
2019
Q2
$123K Sell
1,689
-4,444
-72% -$349K 0.03% 152
2019
Q1
$494K Sell
6,133
-2,178
-26% -$178K 0.11% 108
2018
Q4
$766K Buy
8,311
+187
+2% +$16.4K 0.19% 88
2018
Q3
$768K Buy
8,124
+366
+5% +$34.7K 0.18% 87
2018
Q2
$719K Sell
7,758
-139
-2% -$13.6K 0.18% 83
2018
Q1
$747K Buy
7,897
+675
+9% +$74.2K 0.19% 82
2017
Q4
$698K Buy
7,222
+31
+0.4% +$2.92K 0.17% 95
2017
Q3
$639K Buy
7,191
+67
+0.9% +$5.1K 0.16% 95
2017
Q2
$517K Sell
7,124
-782
-10% -$52.6K 0.13% 102
2017
Q1
$515K Buy
7,906
+4,370
+124% +$275K 0.13% 101
2016
Q4
$222K Sell
3,536
-129
-4% -$7.87K 0.06% 131
2016
Q3
$231K Sell
3,665
-32
-0.9% -$2.07K 0.06% 121
2016
Q2
$228K Sell
3,697
-448
-11% -$27.3K 0.07% 121
2016
Q1
$236K Sell
4,145
-451
-10% -$25.1K 0.07% 119
2015
Q4
$272K Buy
4,596
+54
+1% +$3.11K 0.08% 112
2015
Q3
$247K Buy
4,542
+1,434
+46% +$93.3K 0.08% 108
2015
Q2
$208K Buy
3,108
+1,149
+59% +$75K 0.07% 115
2015
Q1
$115K Buy
1,959
+500
+34% +$30.2K 0.04% 144
2014
Q4
$95K Buy
1,459
+300
+26% +$18.9K 0.03% 152
2014
Q3
$67K Buy
1,159
+759
+190% +$42.1K 0.03% 159
2014
Q2
$22K Hold
400
0.01% 198
2014
Q1
$20K Hold
400
0.01% 207
2013
Q4
$22K Hold
400
0.01% 198
2013
Q3
$18K Hold
400
0.01% 211
2013
Q2
$17.5K Buy
+400
New +$17.5K 0.01% 215

Other funds holding ABBV

Central Bank & Trust's ABBV Position: Q2 2026 in Review

Central Bank & Trust increased its AbbVie (ABBV) stake by 422% in Q2 2026, buying an estimated $1.92M and bringing the position to 11,017 shares worth $2.77M. The position accounts for 0.39% of the portfolio, ranked #63.

Central Bank & Trust first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Central Bank & Trust held 11,017 shares of AbbVie worth $2.77M as of Q2 2026.
  • Central Bank & Trust bought 8,905 AbbVie shares in Q2 2026, an estimated $1.92M.
  • AbbVie made up 0.39% of Central Bank & Trust's portfolio in Q2 2026, its #63 holding.
  • Central Bank & Trust first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Central Bank & Trust's 13F filing for Q2 2026, filed 17 Jul 2026.